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ABSTRACT 
Floating drug delivery systems are the gastroretentive forms that precisely control the release rate of target drug to a specific site which 
facilitate an enormous impact on health care. The purpose of this research was to develop a novel gastro retentive drug delivery system based 
on direct compression method for sustained delivery of active agent to improve the bioavailability, reduce the number of doses and to increase 
patient compliance. Gastro retentive floating tablets of Prochlorperazine dimaleate (PCZ) were prepared by direct compression method using 
altered concentrations of HPMC K4, HPMC K15 and PVP K30 as polymers. The prepared tablets of PCZ were evaluated for hardness, thickness, 
friability, weight variation, drug content uniformity, buoyancy lag time, total floating time, in-vitro dissolution study, etc. All the compositions 
were resulted in adequate Pharmacopoeial limits. Compatibility studies was execution during FTIR shown that there was absence of probable 
chemical interaction between pure drug and excipients. The varying concentration of gas generating agent and polymers was fou nd to affect on 
in-vitro drug release and floating lag time. In vitro drug release of floating gastro retentive tablet of PCZ shown that the formulation F9 was 
found to be the best formulation as it releases 98.89% in a controlled manner for an extended period of time (up to 12 hrs).  The release data 
was fitted to various mathematical models such as Higuchi, Korsmeyer-Peppas, First order and Zero order to evaluate the kinetics and 
mechanism of the drug release. The optimized formulation (F9) showed no significant change in physical appearance, drug content, floating lag 
time, in vitro dissolution studies after 75%±5% RH at 40±20C relative humidity for 6 months.  Prepared floating tablets of PCZ may prove to be 
a potential candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive dr ug delivery system. 
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INTRODUCTION  
The oral route is considered as the most promising route of 
drug delivery. Drugs with narrow absorption window in the 
GIT have poor absorption1.
 
Therefore, Grdds have been 
developed, which prolong gastric emptying time of drug and 
offers numerous advantages; improves bioavailability, 
reduces drug waste and improves solubility for drugs that 
are less soluble in a high pH environment of small intestine2.
 
To formulate a successful stomach specific or gastroretentive 
drug delivery system, several techniques are currently used 
such as HBS or floating drug delivery systems, low density 
systems, raftsystems, incorporating alginate gels, 
bioadhesive or mucoadhesive systems, super porous 
hydrogels and magnetic systems. Swellable, floating and SR 
tablets are developed by using a combination of hydrophilic 
polymers (HPMC), swelling agents (crosspovidone and 
crosscarmellose sodium) and effervescent substances 
(NaHCO
3 
and citric acid). Prochlorperazine dimaleate (also 
known as Prochlorperazin, Compazine, Capazine, Stemetil), 
the dimaleate salt of Prochlorperazine, is a dopamine (D2) 
receptor antagonist that belongs to the phenothiazine class 
of antipsychotic agents that are used for the antiemetic 
treatment of nausea and vertigo. It is also a highly potent 
typical antipsychotic, 10–20 times more potent than 
chlorpromazine. Prochlorperazine dimaleate is also used to 
treat migraine headaches. The objective of the present 
research work was to provide gastroretentive formulation 
that will provide once daily, sustained release dosage form of 
PCZ3.  
MATERIALS AND METHODS 
Materials 
Prochlorperazine dimaleate was purchased from Sigma 
Aldrich-Merck, Bengaluru, Karnataka, India. Hydroxypropyl 
methylcellulose (HPMC K4M, HPMC K15M) was procured 
from Meditab Specialities Pvt. Ltd., Satara. PVP K30 was 
purchased from S.D fine chemicals, Mumbai. Sodium 
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bicarbonate, Citric acid, magnesium stearate, talc were 
purchased from Mapromax, Life sciences Pvt. Ltd., Dehradun. 
Other solvents and chemicals used in the research were of LR 
grade. All the studies were carried in distilled water. 
Methods 
Preformulation studies 
Standardization of PCZ by UV-Visible spectrophotometry 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1 N HCl solutions in 10 ml of volumetric flask. The resulted 
solution 1000µg/ml and from this solution 1 ml pipette out 
and transfer into 10 ml volumetric flask and volume make up 
with 0.1 N HCl solution and prepare suitable dilution to make 
it to a concentration range of 2-10μg/ml. The spectrum of 
this solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+).  
Fourier transform infrared (FTIR) spectroscopy 
The physical properties of the physical assortment were 
comparing with those of lafutidine pure drug. Samples was 
assorted comprehensively through 100mg potassium 
bromide IR powder as well as compacted under vacuum at a 
pressure of concerning 12 psi for 3 minutes. The ensuing disc 
was mounted in an appropriate holder in Brukers Alpha IR 
spectrophotometer and the IR spectrum was recorded from 
3500 cm to 500 cm. The resultant spectrum was compared 
for any spectrum changes. 
Pre compression evaluation 
Flow properties and compressibility properties of powder 
mixture were evaluated by measurement of angle of repose, 
bulk density, tapped density, carr’s index, and hausner ratio. 
Angle of repose (θ) 
The angle of repose was determined by using fixed funnel 
method. The physical mixtures of drug with different 
excipients were prepared and the accurately weighed drug 
powder or its physical mixture was taken in a funnel. The 
height of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of the drug 
powder. The powder was allowed to flow through the funnel 
freely onto surface. The angle of repose was calculated using 
the following equation. 
θ = tan-1(h/r) 
Where, h and r are the height and radius of the powder cone 
respectively. 
Bulk density 
Both loose bulk density (LBD) and tapped density (TBD) 
were determined were calculated using the following 
formulas. 
LBD = Powder weight/volume of the packing 
TBD = Powder weight /tapped volume of the packing 
Compressibility index 
 The compressibility index of the granules was determined 
by Carr’s compressibility index. 
Carr’s index (%) = [(TBD – LBD)/TBD] × 100. 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of measuring the 
powder flow. It was calculated by the following formula4-6. 
Hausner’s ratio = Tapped density/Bulk density. 
Formulation development of tablets 
Direct compression method 
Different tablets formulations (F1-F9) were prepared by 
direct compression technique. All powders were passed 
through 40 meshes. Required quantities of drug and 
polymers were mixed thoroughly Magnesium stearate was 
added as lubricant. Talc was used as glidant. Lactose was 
used as diluents. Finally the powder mix was subjected to 
compression after mixing uniformly in a polybag. Prior to 
compression, the blends were evaluated for several tests7. 
The composition of PCZ floating tablets was shown in Table 
1.
 
Table 1 Formulation composition of PCZ gastro retentive tablets 
 
Evaluation of tablets 
All the tablets were evaluated for following different 
parameters which includes; 
General appearance 
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, shape 
were evaluated. Appearance was judged visually. 
Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used, and 
an average value was calculated. 
Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Excipients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Prochlorperazine 
Dimaleate 
5 5 5 5 5 5 5 5 5 
HPMC K 15 80 100 120 - - - 40 50 60 
HPMC K 4 - - - 80 100 120 40 50 60 
PVP K30 15 15 15 15 15 15 15 15 15 
Citric acid 5 5 5 5 5 5 5 5 5 
NaHCO3 20 20 20 20 20 20 20 20 20 
Mg(C18H35O2)2 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Lactose 65 45 25 65 45 25 65 45 25 
Total Weight 200 200 200 200 200 200 200 200 200 
Patle et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):445-450 
ISSN: 2250-1177                                                                                  [447]                                                                                 CODEN (USA): JDDTAO 
Friability 
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab).Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N HCl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and analyzed for drug content by UV 
spectrophotometer at a λmax of 256 nm using of 0.1 N HCl as 
blank. 
In vitro buoyancy studies 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al8. The tablets were 
separately in a 100 ml glass beaker containing simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time necessary for 
the tablet to increase to the outside and float was determined 
as floating lag time. The experiments were conducted in 
triplicate. Total floating times were measured during in 
vitro dissolution studies. 
Dissolution rate studies 
In vitro drug release of the sample was done using USP-type 
II dissolution apparatus (Paddle type). The dissolution 
medium, 900 ml 0.1N HCl was set into the dissolution flask 
maintaining the temperature of 37±0.50c and rpm of 75. One 
PCZ tablet was set in every container of dissolution 
apparatus. The mechanical assembly was permitted to keep 
running for 10 hours. Sample measuring 5 ml were pulled 
back after each 1 hour up to 10 hours using 10ml pipette. 
The new disintegration medium (370C) was supplanted each 
time with a similar amount of the sample and takes the 
absorbance at 256 nm using spectroscopy9-11. 
Mathematical treatment of in-vitro release data: The 
quantitative analysis of the qualities got in 
dissolution/release tests is simpler when mathematical 
formulas that express the dissolution comes about as an 
element of a portion of the measurement frames attributes 
are utilized. 
Zero-order kinetics: The pharmaceutical dosage frames 
following this profile release a similar measure of medication 
by unit of time and it is the ideal method of medication 
release keeping in mind the end goal to accomplish a 
pharmacological prolonged action. The following relation 
can, in a simple way, express this model: 
Qt = Qo + Ko t 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution (most times, Qo=0) and 
Ko is the zero order release constant. 
First-order kinetics: The following relation expresses this 
model: 
 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution and K1 is the zero 
order release constant. 
Along these lines a graphic of the decimal logarithm of the 
released measure of drug versus time will be linear. The 
pharmaceutical dosage shapes following this dissolution 
profile, for example, those containing water-solvent drugs in 
permeable frameworks, discharge drug in a way that is 
corresponding to the measure of drug staying in its inside, in 
such way, that the measure of drug released by unit of time 
reduce. 
Higuchi model: Higuchi built up a few theoretical models to 
ponder the arrival of water-solvent and low dissolvable 
medications in semi-strong or potentially strong grids. 
Mathematical expressions were acquired for sedate particles 
scattered in a uniform grid acting as the diffusion media. The 
simplified Higuchi model is expressed as: 
 
Where Q is the amount of drug released in time t and KH is 
the Higuchi dissolution constant. Higuchi model describes 
drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be utilized to 
portray the drug dissolution from a few kinds of modified 
release pharmaceutical dosage structures, for example, 
transdermal systems and matrix tablets with water-
dissolvable drugs. 
Korsmeyer-Peppas model: Korsmeyer et al. used a simple 
empirical equation to describe general solute release 
behaviour from controlled release polymer matrices:  
 
where Mt/M is fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional exponent 
for drug release. ’n’ is the slope value of log Mt/M  versus log 
time curve. Peppas stated that the above equation could 
adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release 
mechanism. Peppas used this n value in order to characterize 
different release mechanisms, concluding for values for a 
slab, of n =0.5 for fickian diffusion and higher values of n, 
between 0.5 and 1.0, or n =1.0, for mass transfer following a 
non-fickian model. In case of a cylinder n =0.45 instead of 
0.5, and 0.89 instead of 1.0. This equation can only be used in 
systems with a drug diffusion coefficient fairly concentration 
independent. To the determination of the exponent n the 
portion of the release curve where Mt/M  < 0.6 should only 
be used. To use this equation it is also necessary that release 
occurs in a one-dimensional way and that the system width-
thickness or length-thickness relation be at least 10. A 
modified form of this equation was developed to 
accommodate the lag time (l) in the beginning of the drug 
release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this equation 
becomes: 
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In the absence of lag time or burst effect, l and b value would 
be zero and only atn is used. This mathematical model, also 
known as Power Law, has been used very frequently to 
describe release from several different pharmaceutical 
modified release dosage forms12-14. 
Stability studies  
The optimized formulation of PCZ were packed in strips of 
0.04 mm thick aluminum foil laminated with poly vinyl 
chloride by strip packing and these packed formulations 
were stored in ICH certified stability chambers (Thermo labs, 
Mumbai) maintained at 40 0C and 75% RH for 6 months. The 
samples were withdrawn periodically and evaluated for their 
floating lag time, content uniformity and for in vitro drug 
release. 
RESULTS AND DISCUSSION 
The λ max of PCZ was found to be 256 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 2-
10µg/ml Figure1, 2. Identification of betahistine was done by 
FTIR spectroscopy with respect to marker compound. It was 
identified from the result of IR spectrum as per specification. 
Tablet powder blend was subjected to various pre-
formulation parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density and tapped density of all the formulations 
was found to be in the range of 0.349to 0.365 (gm/ml) and 
0.438 to0.485 showing that the powder has good flow 
properties. The compressibility index of all the formulations 
was found to be ranging between 20.320 to 26.186which 
shows that the powder has good flow properties. All the 
formulations have shown the Hauser’s ratio ranging between 
1.255to 1.355indicating the powder has good flow 
properties. PCZ tablet quality control tests such as weight 
variation, hardness and friability, thickness, drug content 
and drug release studies in different media were performed 
on the compression tablet. All the parameters such as weight 
variation, hardness, friability, thickness and drug content 
were found to be within limits Table 3.  
 
Figure 1 Determination of λmax of prochlorparazine 
dimeliate 
 
Figure 2 Calibration curve of prochlorperazine 
dimaleate at 256 nm
 
Table 2 Result of pre-compression properties of PCZ FGR tablets 
Formulation 
code 
Bulk 
density(gm/ml) 
Tapped 
density(gm/ml) 
Compressibility 
index 
Hausner ratio 
F1 0.356 0.462 22.944 1.298 
F2 0.359 0.458 21.616 1.276 
F3 0.365 0.469 22.175 1.285 
F4 0.362 0.472 23.305 1.304 
F5 0.358 0.485 26.186 1.355 
F6 0.359 0.478 24.895 1.331 
F7 0.354 0.469 24.520 1.325 
F8 0.358 0.458 21.834 1.279 
F9 0.349 0.438 20.320 1.255 
 
Table 3 Results of post compression properties of PCZ FGR tablets 
F. Code Thickness 
(mm) 
Diameter 
(mm) 
Hardness (kg/cm2) 
N=3 
Weight 
variation (mg) 
Friability 
(%) 
Drug content 
(%) 
F1 3.46 9.8 4.8 205 0.589 98.85 
F2 3.50 9.6 4.6 198 0.685 96.65 
F3 3.47 9.8 4.7 200 0.458 99.56 
F4 3.48 9.7 4.8 203 0.658 98.25 
F5 3.49 9.8 4.6 205 0.521 97.85 
F6 3.45 9.6 4.5 195 0.658 98.98 
F7 3.44 9.5 4.8 203 0.965 99.12 
F8 3.43 9.7 4.7 205 0.658 99.45 
F9 3.46 9.8 4.8 201 0.785 99.36 
 
In the present study 9 formulations with variable 
concentration of polymers (HPMC K4, K 15) were prepared 
by direct compression method and evaluated for  
 
physicochemical properties. The results of buoyancy lag 
time, total floating time and in vitro drug release was given 
in Table 4, 5 & Fig.3. The results indicated that optimizes 
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formulation F9 on immersion in 0.1N HCl at 37±0.50C tablets 
immediately and remain buoyant up to 12hr without 
disintegration. These 2 factors are essential for tablets to 
acquire density< 1, so that it remains buoyant on the gastric 
fluids. The in vitro drug release data of the optimized 
formulation was subjected to goodness of fit test by linear 
regression analysis according to zero order, first order 
kinetic equation, higuchi’s and korsmeyer’s models in order 
to determine the mechanism of drug release. When the 
regression coefficient values of were compared, it was 
observed that ‘r’ values of Korsmeyer Peppas was maximum 
i.e. 0.977 hence indicating drug release from formulations 
was found to follow Korsmeyer Peppas model. Table 6, 7 & 
Fig. 4-7.  
Table 4 Results of in-vitro buoyancy study of PCZ FGR  
Formulation 
Code 
Floating lag times 
(sec) 
Total floating 
duration (h) 
F1 65 12 Hrs. 
F2 69 12 Hrs. 
F3 85 12 Hrs. 
F4 69 12 Hrs. 
F5 45 12 Hrs. 
F6 52 12 Hrs. 
F7 39 12 Hrs. 
F8 49 12 Hrs. 
F9 55 12 Hrs. 
 
Table 5 In-vitro drug release study of GRF tablets 
Time  % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 48.56 45.58 40.25 38.89 36.25 33.25 28.45 26.65 23.36 
1 78.89 75.56 68.98 49.98 42.25 40.56 36.45 30.35 26.69 
1.5 89.98 82.23 79.78 65.58 58.98 50.56 45.58 40.56 38.78 
2 96.56 95.56 88.78 78.89 75.58 70.25 65.56 61.25 45.25 
3  98.98 95.56 90.12 88.98 81.25 73.32 70.25 55.56 
4   98.89 95.56 95.56 90.25 88.98 83.25 68.89 
6    98.89 99.89 98.65 98.45 93.56 78.58 
8        98.78 89.98 
12         98.89 
 
 
Figure 3 In-vitro drug release study of GRF tablets 
Table 6 In-vitro drug release data for optimized formulation F9 
Time 
(h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative % 
Drug Remaining 
0.5 0.707 -0.301 23.36 1.368 76.64 1.884 
1 1 0 26.69 1.426 73.31 1.865 
1.5 1.225 0.176 38.78 1.589 61.22 1.787 
2 1.414 0.301 45.25 1.656 54.75 1.738 
3 1.732 0.477 55.56 1.745 44.44 1.648 
4 2 0.602 68.89 1.838 31.11 1.493 
6 2.449 0.778 78.58 1.895 21.42 1.331 
8 2.828 0.903 89.98 1.954 10.02 1.001 
12 3.464 1.079 98.89 1.995 1.11 0.045 
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Figure 4 Zero order release Kinetics  
 
Figure 5 Fig. 5 First order release kinetics  
 
Figure 6 Higuchi release Kinetics  
 
Figure 7 Korsmeyer-Peppas release Kinetics
 
Table 7 Regression analysis data of Prochlorperazine dimaleate Floating Tablets 
Batch 
Zero Order First Order Higuchi  Korsmeyer Peppas 
R² R² R² R² 
F9 0.895 0.959 0.975 0.977 
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CONCLUSION 
PCZ floating tablets were successfully formulated by floating 
technique. The optimized formulation (F9) was selected on the 
basis of in vitro buoyancy and in vitro drug release. The 
addition of gel forming agent and gas generating agent was 
essential to achieve in vitro buoyancy. The results of the in 
vitro drug release and in vitro buoyancy study showed that the 
optimized formulation (F9) sustained the drug release 
(98.89%) up to 12 hrs and remained buoyant for >12 hrs. 
Optimized formulation (F9) does not show any significant 
change in physical appearance, floating properties and drug 
release after storage at 40°C/75% RH and stable for 3 months. 
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